AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02513004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
Study NCT02432339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil (MMF)
Description: an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
Study NCT02432339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
Study NCT02410408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apps Root Cause Analysis or patient safety ISO certification
Description: Apps for conducting RCA or PSC
Study NCT02410408 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information package
Description: Information on PSC and RCA
Study NCT02881658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant sterols-enriched soya beverage provided by Vitasoy
Description: the study product is a 2g plant sterols-enriched in 250ml soya beverage
Study NCT02881658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soya beverage provided by Vitasoy
Description: the placebo product is a 250 ml soya beverage
Study NCT02355717 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Study NCT01055015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: IR Capsules, flexible dose, every 4 to 6 hours
Study NCT01055015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)
Description: One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
Study NCT01644097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain 299v
Description: Given PO
Study NCT01644097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus probiotic
Description: Given PO
Study NCT01644097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01644097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01644097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01644097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01644097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01644097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01644097 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01644097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis probiotic supplement
Description: Given PO
Study NCT03719430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
Study NCT03719430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX005M
Description: APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
Study NCT02396225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Study NCT02396225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Study NCT01935999 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: One piece closed pouch
Description: A one piece closed pouch for the collection of stool from a colostomy stoma
Study NCT01214993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
Study NCT01214993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a tablet with no drug in it.
Study NCT01214993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol Injection
Description: Iohexol is an FDA approved radiologic contrast medium
Study NCT01214993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iohexol Injection
Description: Iohexol is an FDA approved radiologic contrast medium
Study NCT01214993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-aminohippurate infusion
Description: Para-aminohippurate is an agent to measure effective renal plasma flow.
Study NCT01214993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Para-aminohippurate infusion
Description: Para-aminohippurate is an agent to measure effective renal plasma flow.
Study NCT01417468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLSI, MI, CR
Description: (CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
Study NCT01417468 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CLSI - Unknown
Description: (CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
Study NCT03819517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: Over the counter supplementation
Study NCT03819517 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty white colored soft vegetarian capsule
Study NCT03433235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: 1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS >16)~- NIHSS: National Institute of Health Stroke Scales
Study NCT03433235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: 1-3-6-12 rule\*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS \<8)~After 6 days: moderate ischemic strokes (NIHSS 8-16)~After 12 days: severe ischemic strokes (NIHSS >16)~- NIHSS: National Institute of Health Stroke Scales
Study NCT06034093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time AI-assisted muscle ultrasound
Description: RAIMUS software provides automatic segmentation and size measurement for the RFCSA
Study NCT01666561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Test Cereal 1, Oat based
Description: The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
Study NCT01666561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast Test Cereal 2, Oat-based
Description: The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
Study NCT01666561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready-to-eat cereal
Description: The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
Study NCT02884739 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT00311688 — intervention group
Intervention type: DRUG
Intervention: Interleukin-2
Description: Biological response modifier in liquid form; dosage of drug will vary by study
Study NCT02077998 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon C 14 oxaliplatin
Description: Given IV
Study NCT02077998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT02077998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02619617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM230
Description: The study evaluated SOM230 vs Placebo
Study NCT02619617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The study evaluated SOM230 vs Placebo
Study NCT03459716 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04658797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A Daily Disposable Contact Lens
Description: Daily Disposable Contact Lens
Study NCT04658797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Vision Spectacle for Vision Correction
Description: Single Vision Spectacle
Study NCT06729398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS
Description: NIRS is placed on the frontoparietal once the neonates born in the delivery room until 72 hours
Study NCT06729398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SafeboosC
Description: SafeboosC treatment guideline is used to maintain normal value of cerebral rStO2.
Study NCT03632941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRP-HER2
Description: VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
Study NCT03632941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRP-HER2
Description: VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
Study NCT03632941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
Study NCT03632941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
Study NCT05202873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gait analysis
Description: Gait assessment will be performed using a non-invasive device. It is the BTS G-sensor inertial sensor (BTS Bioengineering, Garbagnate Milanese, Italy). The spatiotemporal variables of gait will be studied from the Walk+ protocol, in which the participant navigates a 7-meter hallway six times, completing three round trips with necessary turns at each end to change direction.
Study NCT03514316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel Gingivectomy
Description: The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.
Study NCT03514316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Gingivectomy
Description: In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor
Study NCT03514316 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nonsurgical periodontal treatment
Description: In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
Study NCT04658797 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personal Facemask
Description: Personal Facemask
Study NCT04658797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal Facemask
Description: Personal Facemask
Study NCT00910598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate
Description: 20 mg daily s.c. for 1 year
Study NCT02948829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.
Study NCT05885451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 592
Description: Administered as SC injection
Study NCT05885451 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as SC injection
Study NCT00814138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
Study NCT00814138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly
Study NCT01222208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutrition with dextrose and pressurized whey protein
Description: Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
Study NCT01222208 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral Parenteral Nutrition
Description: Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
Study NCT00327223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imexon
Study NCT04175132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foliglurax
Description: Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
Study NCT04175132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foliglurax
Description: Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
Study NCT03485534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: Viread 300mg
Study NCT03485534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil
Description: Virehepa 245mg
Study NCT00737100 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat
Description: patient to receive placebo matching active drug once daily
Study NCT00737100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide 5 mcg
Description: patient to recieve high dose tiotropium once daily
Study NCT00737100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide-low dose-2.5mcg
Description: patient to receive low dose tiotropium once daily
Study NCT01414478 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Shake
Description: Protein shake contains 30 grams of protein in 11 fluid ounces.
Study NCT04474262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
Study NCT04474262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)
Study NCT04474262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine Oral Tablet
Description: Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).
Study NCT04474262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03099460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular electroacupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0\~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
Study NCT03099460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocular acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
Study NCT03099460 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
Study NCT01768780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine
Description: The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle.
Study NCT01301261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: Sugammadex 2 mg/kg when a two count of train of four appears
Study NCT01301261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 4 mg/kg
Description: Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
Study NCT01301261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 16mg/kg
Description: Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
Study NCT00275171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human thyrotropin (Thyrogen)
Description: 0.1 mg rhTSH administered intramuscularly
Study NCT00275171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human TSH
Description: 0.1 mg rhTSH administered intramuscularly
Study NCT00275171 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline = placebo
Description: 0.1 mg isotonic saline injected intramuscularly
Study NCT04281082 — intervention group
Intervention type: DRUG
Intervention: ursofalk
Description: To study the genetic polymorphisms in pregnant women with ICP treated with ursoflak and in their first degree relatives
Study NCT02962310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Rosuvastatin Calcium Tablets 40 mg
Description: oral, crossover